GoodRx Holdings, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the Annual Meeting of Stockholders held by GoodRx Holdings, Inc. on June 14, 2022. The filing details the voting results for three proposals submitted to shareholders.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting outcomes.
Material Changes and Voting Results
Approximately 98.8% of the combined voting power of Class A and Class B common stock was present or represented by proxy. The following proposals were approved:
- Election of Directors: Christopher Adams, Trevor Bezdek, and Adam Karol were elected as Class II directors for a term expiring in 2025. All three received over 3.15 billion votes in favor.
- Ratification of Auditors: PricewaterhouseCoopers LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2022, with over 3.18 billion votes in favor.
- Executive Compensation Vote Frequency: Shareholders approved holding an advisory vote on executive compensation annually (One Year frequency) with over 3.15 billion votes in favor.
Guidance, Outlook, and Risks
The filing does not contain management commentary on financial guidance, outlook, risks, contingencies, or unusual items. The Company confirmed it will hold annual advisory votes on executive compensation based on the shareholder approval.
Key Facts for Investors to Verify
- Confirmation of the new board composition following the election of the three Class II directors.
- The specific engagement terms with PricewaterhouseCoopers LLP for the 2022 fiscal year.
- Future dates for the annual advisory votes on executive compensation.